Takeda Pharmaceutical and the Indonesian Government have launched a landmark collaboration to build the country’s plasma ecosystem and secure sustainable access to plasma-derived medicinal products. The multi-year initiative, marked by a fractionation license granted to Takeda by the Ministry of Health, is the first of its kind in the ASEAN region. As part of the initial phase, Takeda will invest up to $30 million over a two-year pilot program to establish a network of high-quality plasma donation centers starting in 2027. The facilities will integrate into Takeda’s global BioLife network, adhering to strict international regulatory standards, and while local centers scale up, plasma collected in Indonesia will be processed across Takeda’s global manufacturing footprint with priority allocation directed back to meet Indonesian domestic healthcare needs. Beyond the initial pilot, Takeda and the government will assess the feasibility of constructing a state-of-the-art plasma manufacturing facility in Indonesia to feed both regional and global supply chains.
Takeda Pharmaceutical Co. Ltd.Takeda invests $30M and secures a fractionation license, expanding its plasma business in Indonesia.